28.69

0.91% 0.5413

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $28.69, with a volume of 7.62M. It is up +0.91% in the last 24 hours and down -13.50% over the past month. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Previous Close:

$28.15

Open:

$28.14

24h Volume:

7.62M

Relative Volume:

0.46

Market Cap:

$6.69B

Revenue:

$2.35B

Net Income/Loss:

$128.37M

P/E Ratio:

54.95

EPS:

0.5221

Net Cash Flow:

$57.42M

1W Performance:

-10.59%

1M Performance:

-13.50%

6M Performance:

+74.59%

1Y Performance:

-38.28%

1-Day Range:

$27.51

$28.73

1-Week Range:

$27.51

$31.79

52-Week Range:

$13.74

$65.30

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

2,442

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	28.67	6.57B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	17.35	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.52	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.585	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.58	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	507.18	21.43B	3.17B	1.29B	1.01B	27.09

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	JP Morgan	Overweight
Mar-10-26	Upgrade	BofA Securities	Underperform → Neutral
Mar-10-26	Upgrade	Citigroup	Sell → Neutral
Mar-09-26	Upgrade	Needham	Hold → Buy
Feb-24-26	Downgrade	BTIG Research	Buy → Neutral
Jan-12-26	Initiated	Evercore ISI	In-line
Dec-09-25	Initiated	Barclays	Overweight
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy
Apr-29-25	Downgrade	TD Cowen	Buy → Hold
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

01:36 AM

Hims & Hers Stock (HIMS) Opinions on Five-Year Public Listing Anniversary - Quiver Quantitative

01:36 AM

10:58 AM

Financial Markets Wall Street - Dayton Daily News

10:58 AM

03:07 AM

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - Stocktwits

03:07 AM

02:38 AM

5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call - Yahoo Finance

02:38 AM

Aug 16, 2026

HIMS Stock Climbs Overnight: Oscar Health CEO Courts Hims For New Drug Marketplace - Stocktwits

Aug 16, 2026

Aug 15, 2026

Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks - Stocktwits

Aug 15, 2026

Hims & Hers Health (NYSE:HIMS) Upgraded to Hold at Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Hims & Hers Health, Inc. • Robinhood Token Price, HIMS Price, Live Charts, and Marketcap - Coinbase

Aug 14, 2026

Hims & Hers Health CTO Mohamed Elshenawy Awarded 1.2 Million RSUs - Kalkine Media

Aug 14, 2026

Hims & Hers Health Director Christopher D. Payne Awarded 8,768 RSUs in August 2026 - Kalkine Media

Aug 14, 2026

Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset? - Yahoo Finance

Aug 14, 2026

Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop - pluang.com

Aug 14, 2026

Hims & Hers Health's Next Act: Making Its Own Drugs Again (NYSE:HIMS) - Seeking Alpha

Aug 14, 2026

Investor relations - HIMS investor relations

Aug 14, 2026

Aug 13, 2026

Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review

Aug 13, 2026